CoDiagnostics
Open
$1.58
Prev. Close
$1.58
High
$1.58
Low
$1.55
Market Snapshot
$3.11M
-0.1
-37.20
$3.92M
132
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
emptyResult
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Recently from Cashu
CoDiagnostics Advances with Manufacturing Facility in Saudi Arabia's Molecular Diagnostics Landscape
CoDiagnostics Expands its Footprint in Saudi Arabia's Molecular Diagnostics Sector CoDiagnostics, Inc., through its joint venture CoMira Diagnostics, marks a significant milestone with the recent allo…
CoDiagnostics Innovates TB Testing with New PCR-based Solutions and Clinical Studies Launch
CoDiagnostics Advances Tuberculosis Testing with Innovative Solutions CoDiagnostics, Inc. is set to enhance tuberculosis (TB) diagnostic capabilities through the anticipated launch of clinical perform…
CoSara Innovates Healthcare in India with Localized Diagnostic Solutions and Expansion Plans
CoSara Aims to Transform Healthcare with Advanced Diagnostic Solutions in India CoSara, the joint venture between Co-Diagnostics, Inc. (Co-Dx) and Ambalal Sarabhai Enterprises Limited, is poised to re…
CoDiagnostics Showcases Innovations at Medical Korea 2026 to Expand Global Presence
CoDiagnostics Strengthens International Presence at Medical Korea 2026 CoDiagnostics, Inc., a leader in molecular diagnostics, prepares to showcase its innovative diagnostic solutions at Medical Korea…